Crescent Biopharma (NASDAQ:CBIO – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Profitability
This table compares Crescent Biopharma and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crescent Biopharma | N/A | -103.44% | -88.19% |
| Xenetic Biosciences | -70.03% | -39.28% | -33.47% |
Institutional and Insider Ownership
75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crescent Biopharma | 1 | 0 | 4 | 1 | 2.83 |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Crescent Biopharma presently has a consensus price target of $29.00, indicating a potential upside of 56.89%. Given Crescent Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than Xenetic Biosciences.
Valuation & Earnings
This table compares Crescent Biopharma and Xenetic Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crescent Biopharma | $10.84 million | 46.99 | -$153.94 million | ($10.91) | -1.69 |
| Xenetic Biosciences | $2.98 million | 2.26 | -$2.68 million | ($1.20) | -2.45 |
Xenetic Biosciences has lower revenue, but higher earnings than Crescent Biopharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Crescent Biopharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.
Summary
Crescent Biopharma beats Xenetic Biosciences on 9 of the 15 factors compared between the two stocks.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
